2026 FDA Rules on Compounded Tirzepatide: What Med Spas and Telehealth Clinics Need to Know Right Now

If your clinic built any part of its weight loss program around compounded tirzepatide, 2026 is the year to stop assuming your existing process is still compliant. The FDA has moved decisively on this front, and what worked operationally in 2023 or 2024 — when a genuine national shortage created real compounding flexibility — is largely gone now. Here's exactly where things stand as of this writing, and what that means for how your clinic sources, prescribes, and talks to patients.

Why the Shortage Ending Changed Everything

Tirzepatide, the active ingredient in Mounjaro and Zepbound, is regulated under Section 503A and 503B of the Food, Drug & Cosmetic Act, both of which give pharmacies more flexibility to compound a version of an FDA-approved drug during an official shortage. The FDA determined the tirzepatide shortage had ended by October 2024, reaffirming that position that December. Enforcement discretion for 503A pharmacies compounding tirzepatide ended February 18, 2025, and for 503B outsourcing facilities on March 19, 2025. Semaglutide's shortage was declared resolved shortly after, in February 2025.

Once a shortage designation lifts, the legal basis for broad compounding lifts with it. Many clinics built recurring revenue — membership programs, monthly injection packages, telehealth subscriptions — during the years compounding was more permissive. That growth happened fast, and a lot of it didn't get rebuilt on a compliant foundation once the shortage flexibility disappeared.

The April 2026 Proposal That Changes the Picture Further

On April 30, 2026, the FDA went a step further, proposing to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list entirely. That list determines which active ingredients outsourcing facilities are permitted to use for large-scale compounding outside of a shortage designation. The FDA's stated reasoning was direct: after reviewing the nominations submitted for these three substances, the agency did not find sufficient evidence of clinical need — meaning no attribute of the FDA-approved products (Ozempic, Wegovy, Mounjaro, Zepbound, Victoza, Saxenda) made them medically unsuitable for the patients who'd otherwise seek a compounded version. Cost, convenience, and general supply preference were explicitly excluded from that clinical-need analysis.

The comment period on this proposal, originally scheduled to close June 29, 2026, was subsequently extended to July 30, 2026 in response to industry requests for more time to respond. That means, as of today, a final determination hasn't been issued yet — but the direction is about as clear as regulatory signaling gets. If finalized as proposed, this would close the door on large-scale 503B compounding of these three medications entirely, leaving only narrow, patient-specific 503A compounding as a legal pathway, and only where genuine clinical necessity — not cost or preference — can be documented.

Compounded Doesn't Mean FDA-Approved, and Regulators Are Watching That Distinction Closely

This is a point worth being explicit with patients about: a compounded medication, even one prepared by a fully licensed and accredited pharmacy, has not gone through FDA review for safety, effectiveness, labeling, or quality the way an approved drug like Zepbound or Mounjaro has. The FDA has been unambiguous in recent enforcement actions that marketing language implying otherwise — suggesting a compounded product is "the same as" or "as good as" the approved brand — constitutes a compliance violation, and telehealth companies have received formal warning letters over exactly this kind of language.

Adding vitamins, amino acids, or other ingredients and marketing the result as "personalized" doesn't change that calculus either. Regulators have been clear that combining tirzepatide or semaglutide with additives like B12 doesn't, by itself, establish the kind of documented medical necessity required to justify compounding once shortage flexibility ends — and there's emerging research raising open safety questions about compounds formed when these medications are combined with certain additives during mass compounding. "Personalized" language isn't a shortcut around real clinical documentation.

Where Clinics Are Most Exposed Right Now

A few risk areas show up repeatedly in enforcement activity:

Vendor documentation gaps. Confirm every pharmacy's licensing status, whether they're 503A or 503B, their state authorization, and whether they're actually requiring patient-specific prescriptions where the law demands it. Request a current certificate of analysis for every batch. The FDA has documented counterfeit compounded tirzepatide circulating with fabricated pharmacy names on the label — verification isn't optional diligence, it's a real safeguard.

Marketing language that oversteps. Phrases like "same active ingredient as Mounjaro," "generic Zepbound," or anything implying the compounded product carries the same clinical trial backing as the approved medication have drawn direct FDA scrutiny. That audit should cover your website, social media, paid ads, landing pages, and any scripted patient communication — not just formal marketing materials.

Thin medical oversight. GLP-1 prescribing is genuine medical decision-making and needs to be treated that way: full history including BMI and comorbidities, a real medication and supplement review, contraindication screening (particularly for personal or family history of medullary thyroid carcinoma or MEN-2), and documented informed consent — ideally captured the same visit as the prescribing decision, since that's specifically what state boards look for. Structured follow-up at reasonable intervals, with weight, labs, dose changes, and side effects all documented, closes the loop.

Loose inventory and dispensing records. Every dose needs a traceable chain: what was ordered, received, stored, administered or dispensed, and logged, including expiration dates and fridge temperature checks. For 503A-sourced product, every dose needs to map back to a specific patient prescription — stock sitting without that link is exactly what an inspector flags first.

Running a Compliance Check on Your Own Program

A practical audit sequence: revisit every vendor relationship against current licensing and documentation standards, and pause ordering from anyone you can't fully verify. Review every piece of patient-facing language — website, intake forms, consent documents, ads, scripts — for anything implying FDA approval or brand equivalence that isn't accurate. Make sure front desk and non-clinical staff have simple, accurate scripts for common patient questions, with a clear rule that any genuinely clinical question routes straight to a licensed provider. And confirm your documentation actually captures full history, contraindications, consent, and follow-up consistently, not just for your most recent patients.

How to Talk to Patients About This Without Overcomplicating It

Patients are picking up on a confusing mix of headlines and shifting telehealth offers, and the most effective response isn't a regulatory lecture — it's straightforward reassurance backed by real practice. Let them know your clinic follows current state and federal requirements, sources through verified channels, and prioritizes their safety over the cheapest possible option. You don't need to walk a patient through 503A versus 503B distinctions; you do need them to understand that a thorough evaluation, real medical oversight, and reliable, verified sourcing are what actually differentiate your clinic from a bare-bones subscription site with minimal oversight behind it.

This Doesn't Stop at Federal Rules

State medical, nursing, and pharmacy boards are actively enforcing on top of federal requirements, and several have already disciplined telehealth-only prescribers over weight management practices. Corporate Practice of Medicine restrictions, telehealth-specific prescribing rules, and state-level medical director requirements all layer on top of whatever the FDA finalizes on the 503B question — meaning full compliance requires checking both levels, not just the federal headline.

How Wellness MD Group Supports This

This is precisely the kind of shifting regulatory terrain Wellness MD Group is built to help clients navigate — physician-led medical director oversight actively involved in GLP-1 protocol decisions, vendor and pharmacy relationships vetted against current licensing standards, and EHR guidance structured to keep documentation complete and audit-ready as the rules continue to move.

The Bottom Line

2026 isn't the year to assume last year's GLP-1 workflow is still compliant. Between the shortage designations lifting, the pending 503B exclusion decision now due after July 30, and sustained FDA enforcement attention on telehealth and med spa marketing, the clinics in the strongest position are the ones treating this as an ongoing compliance discipline — sourcing, documentation, and patient communication reviewed regularly — rather than a box checked once and left alone.